The recent surge in funding into niche pharmaceutical companies, particularly those focusing on groundbreaking therapies and complex drug development programs, has fueled what some are calling "High Investor Pharma." https://tasneemevxh764110.ampblogs.com/elite-stakeholder-pharma-risky-bet-76967259